GLYC GlycoMimetics, Inc.

12.61
-0.80  -6%
Previous Close 13.41
Open 13.45
Price To book 10.03
Market Cap 310.71M
Shares 24,640,000
Volume 1,055,010
Short Ratio 0.51
Av. Daily Volume 2,440,770

SEC filingsSee all SEC filings

  1. 8-K - Current report 17906653
  2. 8-K - Current report 17870206
  3. 424B5 - Prospectus [Rule 424(b)(5)] 17866695
  4. 8-K - Current report 17865468
  5. 424B5 - Prospectus [Rule 424(b)(5)] 17861938

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrollment completed - announced May 31, 2017. Data updates at ASCO June 5, 2017.
GMI-1271
Acute myeloid leukemia (AML) newly diagnosed and refractory - cancer
Phase 3 initiated June 2015. Enrollment to be completed 2H 2018.
GMI-1070 (rivipansel)
Vaso-occlusive crisis of sickle cell disease

Latest News

  1. GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors
  2. Today's Research Reports on Top Tech Stocks: GlycoMimetics and Acorda Therapeutics
  3. GlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference
  4. Why GlycoMimetics Is Tumbling 13.4% Today
  5. GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting
  6. GlycoMimetics Completes Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of Clinical Trial of GMI-1271
  7. GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
  8. Here's Why GlycoMimetics Rose as Much as 21% Today
  9. GlycoMimetics’ GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia
  10. GlycoMimetics Announces Pricing of Public Offering of Common Stock
  11. Shark Bites: There Wasn't Even a Dip to Buy
  12. GlycoMimetics Announces Proposed Public Offering of Common Stock
  13. Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and GlycoMimetics
  14. ETFs with exposure to GlycoMimetics, Inc. : May 19, 2017
  15. Why GlycoMimetics Is Ripping 19% Higher Today
  16. GlycoMimetics (GLYC) Shows Strength: Stock Jumps 98.7%
  17. Today's Research Reports on Stocks to Watch: GlycoMimetics and Endologix
  18. Here's Why GlycoMimetics (GLYC) Stock Skyrocketed Over 100% Today
  19. Don't Trust the Bounce Yet
  20. GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML

SEC Filings

  1. 8-K - Current report 17906653
  2. 8-K - Current report 17870206
  3. 424B5 - Prospectus [Rule 424(b)(5)] 17866695
  4. 8-K - Current report 17865468
  5. 424B5 - Prospectus [Rule 424(b)(5)] 17861938
  6. 8-K - Current report 17820849
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 17820826
  8. DEF 14A - Other definitive proxy statements 17771634
  9. 8-K - Current report 17685199
  10. S-8 - Securities to be offered to employees in employee benefit plans 17654106